rs11842874 — MCF2L

Intronic variant in MCF2L that acts as a synovial eQTL — A allele carriers have higher MCF2L expression in joint tissue and elevated osteoarthritis risk across large joints

See your personal result for MCF2L

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MCF2L and Osteoarthritis: How a Synovial Gene Shapes Joint Vulnerability

Your joints don't simply wear down mechanically — they're governed by complex molecular signals that determine how the tissues lining them respond to stress, injury, and inflammation. MCF2L, a gene encoding a guanine nucleotide exchange factor11 guanine nucleotide exchange factor
a protein that activates Rho-family GTPases, regulating cytoskeletal dynamics and cell motility, turns out to be one of those governors. A common intronic variant in MCF2L — rs11842874 — quietly shapes how much of this protein your synovial tissue produces, and with it, your baseline susceptibility to osteoarthritis of the knee, hip, and other large joints.

The Mechanism

rs11842874 sits within intron 4 of the MCF2L gene on chromosome 13 and does not change the protein sequence at all. Instead, it acts as a cis-acting expression quantitative trait locus (eQTL)22 cis-acting expression quantitative trait locus (eQTL)
a variant that modulates how much of a nearby gene's mRNA is produced, without altering the gene's coding sequence — specifically in synovial membrane tissue, the thin layer lining joint cavities that secretes lubricating fluid and houses key immune and structural cells.

Shepherd et al. (2015)33 Shepherd et al. (2015) demonstrated through quantitative PCR and RNA sequencing of joint tissues that possession of the A allele correlates with increased MCF2L expression in synovial membrane — but not in cartilage. This tissue-specific eQTL pattern was notable: it was the first OA susceptibility locus shown to operate through the synovium rather than cartilage. Luciferase assays confirmed that several SNPs in linkage disequilibrium with rs11842874 display quantitative differences in regulatory activity at the allelic level, pointing to functional regulatory elements within this intronic block.

MCF2L's connection to osteoarthritis biology runs through nerve growth factor (NGF) signaling44 nerve growth factor (NGF) signaling. MCF2L is involved in neurotrophin-mediated regulation of cell motility in the peripheral nervous system, and NGF is a potent mediator of joint pain and inflammation in OA. This mechanistic link gained clinical credibility when humanized anti-NGF antibodies (such as tanezumab) were shown to reduce pain and improve function in knee OA patients — validating the pathway.

The Evidence

The association between rs11842874 and osteoarthritis is one of the most robustly replicated in the field. Day-Williams et al. (2011)55 Day-Williams et al. (2011) conducted a staged GWAS followed by large-scale replication across European cohorts, ultimately encompassing 19,041 OA cases and 24,504 controls. The combined odds ratio was 1.17 (95% CI: 1.11–1.23, p=2.1×10⁻⁸) per A allele — a genome-wide significant signal and the third established locus for OA overall at the time of publication. Given the additive model, AA homozygotes have approximately 1.17² ≈ 1.37-fold elevated risk relative to GG.

The variant also shows evidence of modifying radiographic severity. Valdes et al. (2012)66 Valdes et al. (2012) genotyped three UK cohorts and found rs11842874 was nominally associated with patellofemoral Kellgren-Lawrence grade as a quantitative trait (p=0.027), though the effect on tibiofemoral severity was less consistent. This suggests the MCF2L locus influences both OA susceptibility and the progression of structural joint damage.

The A allele frequency in populations of European descent is approximately 92%, meaning the risk genotype (AA) is by far the most common configuration — around 78% of Europeans carry it. The protective GG genotype, by contrast, is present in only about 1% of Europeans.

Practical Actions

Carrying the A allele doesn't mean OA is inevitable — it means you have population-typical (or slightly elevated) susceptibility that is worth managing proactively, especially if you're physically active or have other joint risk factors. The primary leverage points are reducing cumulative mechanical stress on joint cartilage and supporting synovial tissue health.

High-impact loading patterns — particularly repetitive eccentric loading like downhill running and jumping — generate compressive forces that accelerate cartilage degradation in susceptible joints. For A allele carriers, the MCF2L-driven synovial response to this stress may be dysregulated. Prioritizing low-impact cardio alternatives (cycling, swimming, elliptical) during high-volume training blocks distributes joint load more favorably.

Type II collagen peptides and undenatured type II collagen (UC-II) have specific evidence in supporting cartilage integrity distinct from the type I collagen peptides used for tendon health. The synovial mechanism in MCF2L-associated OA makes this particularly relevant — the synovium is where the eQTL effect is active. Several clinical trials in OA-susceptible individuals have shown benefit from 40 mg UC-II daily (Arthritis & Rheumatism, 2009) and from 10 g hydrolyzed type II collagen.

Interactions

The MCF2L OA susceptibility locus acts within a broader genetic architecture. Other well-replicated OA GWAS loci include GDF5 (rs143383), which encodes growth differentiation factor 5 and influences joint development and cartilage homeostasis. If you carry risk alleles in both MCF2L and GDF5, the combined load on your joint biology is greater than either alone — though formal compound analyses are limited. The NGF pathway connection also creates potential interaction with pain-processing variants; individuals with both elevated MCF2L expression (A/A at rs11842874) and sensitized pain signaling may have amplified OA symptom burden beyond structural changes alone.

Genotype Interpretations

What each possible genotype means for this variant.

GG Joint-Protective Genotype Beneficial

Homozygous for the protective G allele — lowest MCF2L expression in joint tissue and reduced osteoarthritis risk

You carry two copies of the rare protective G allele at rs11842874. This genotype is present in only about 1% of people of European descent, making it genuinely unusual. The G allele is associated with lower MCF2L expression in synovial tissue and reduced osteoarthritis susceptibility — in the original GWAS, GG individuals had the lowest OA risk, with AA homozygotes having approximately 1.37-fold higher odds. While this doesn't make you immune to joint problems caused by injury, overuse, or structural issues, your synovial biology is less predisposed to the molecular cascade that leads to OA in most people.

AG Partially Protected Intermediate

One protective G allele reduces osteoarthritis risk compared to AA, but risk remains above the GG baseline

In the additive model reported by Day-Williams et al. (2011), each A allele contributes approximately OR 1.17 to OA risk. With one A and one G allele, you sit at the intermediate point — meaningfully below the AA risk level but above the rare GG protective state. The eQTL effect of the A allele on MCF2L expression in synovial tissue is partially present (one copy driving expression upward), but the G allele attenuates this effect.

The AG genotype is more common in populations with higher G allele frequencies — in African-ancestry individuals, where the G allele frequency is ~22%, heterozygosity is more prevalent (approximately 34%). In European-ancestry populations, about 21% carry the AG genotype.

AA Common OA Risk Profile High Risk

Both alleles are the common A variant, associated with elevated osteoarthritis susceptibility

The A allele at rs11842874 acts as a cis-eQTL in synovial membrane tissue, upregulating MCF2L expression. MCF2L encodes a guanine nucleotide exchange factor involved in neurotrophin-mediated cell motility, and its overexpression in the synovium appears to alter the joint's inflammatory and mechanosensory milieu in ways that predispose to OA. Importantly, this effect is tissue-specific — the eQTL operates in synovial membrane but not in cartilage, implicating the synovium as a primary site of risk rather than the cartilage itself.

The SNP's association with OA was replicated across 43,000+ individuals in European cohorts (Day-Williams et al., 2011) and is one of only a handful of OA loci reaching genome-wide significance. The A allele frequency in Europeans is ~92%, so AA homozygosity is the population norm — most people carry this risk profile, which is why broad population-level OA prevalence is so high.